Sign up
Quantellect · Congress · Trade Detail
ALXNAlexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA
RepublicanHouse

Thomas MacArthur sold Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN)

Thomas MacArthur (R-NJ), a U.S. Representative, has disclosed 2 trades in Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN) since 2015, 1 purchase and 1 sale, worth an estimated $16K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).

The trade highlighted here is a sale: Thomas MacArthur sold $1,001 - $15,000 of Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN) on January 27, 2015. Since that trade, ALXN is up +0.00% against the S&P 500 up +341.76%, an outperformance of -341.76%.

Across these filings, Thomas MacArthur has been a balanced trader of ALXN (a buy-to-sell ratio of 1.00). Each row in the table below links to that trade and its post-trade performance versus the market.

Data updated

ALXN trades
2
Disclosed Vol
$16K
Buys
1
50%
Sells
1
50%
Buy / Sell
1.00
ratio
First → Last
2015

Thomas MacArthur's ALXN trades vs the price

ALXN is up +0.00% since Thomas MacArthur sold on January 27, 2015, versus +341.76% for the S&P 500.

Performance since this trade

Price change since trade
+0.00%
S&P 500 change since trade
+341.76%
Outperformance vs S&P 500
-341.76%

All Thomas MacArthur ALXN trades

TradedTypeSizeReturnEst. profit
January 27, 2015SELL$1,001 - $15,000N/A
January 21, 2015BUY$1,001 - $15,000N/A

Estimated profit is shown for buys only, marked to the latest close. It is an estimate and does not net later sells, taxes, or fees.

Thomas MacArthur & ALXN trading FAQ

Is it legal for Thomas MacArthur to trade Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN) stock?

Yes. Members of Congress are allowed to trade individual stocks, including Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.

When did Thomas MacArthur sell ALXN?

Thomas MacArthur disclosed a sale of $1,001 - $15,000 of Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN) on January 27, 2015, according to public STOCK Act filings.

How has ALXN performed since Thomas MacArthur's trade?

Since Thomas MacArthur sold ALXN on January 27, 2015, the stock is up +0.00%, versus +341.76% for the S&P 500 over the same period, an outperformance of -341.76%.

How many times has Thomas MacArthur traded ALXN?

Thomas MacArthur has disclosed 2 ALXN trades since 2015 (1 purchase and 1 sale). Every disclosed trade is listed on this page.

How soon must members of Congress disclose a trade?

Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.

Where can I see all congressional ALXN trades?

Quantellect tracks every disclosed congressional trade in Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA (ALXN) on the Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRA congressional trading page, which aggregates filings across all members of Congress.

Thomas MacArthur's ALXN tradesAll congressional filings for Alexion Pharmaceuticals, Inc. (ALXN) F ILINg S TATUS : New S UBHoLDINg o F : Thomas C MacArthur IRAThomas MacArthur's full profile

Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.